|Table of Contents|

Adverse prognosis risk prediction model of bladder cancer based on bioinformatics and its clinical value analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1474-1479
Research Field:
Publishing date:

Info

Title:
Adverse prognosis risk prediction model of bladder cancer based on bioinformatics and its clinical value analysis
Author(s):
GUO Qingxin1; ZHANG Fuhua2; ZHANG Xuejiao3; JIANG Lili1
1.Department of Urology;2.Department of Emergency;3.Intensive Care Unit,Hongqi Hospital Affiliated to Mudanjiang Medical College,Heilongjiang Mudanjiang 157011,China.
Keywords:
bladder cancer; 7-dehydrocholesterol reductase; non-erythrocytic 2; adverse prognosis; early warning model
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2024.08.019
Abstract:
Objective:Based on bioinformatics analysis,to explore 7-dehydrocholesterol reductase (DHCR7)and non-erythrocytic 2 (SPTBN2) expression characteristics in bladder cancer (BLCA),and analyze its clinical application value as an early warning model of poor prognosis in BLCA.Methods:The expression characteristics of DHCR7 and SPTBN2 in BLCA tissues were evaluated using the Gene Expression Profiling Interactive Analysis (GEPIA) website.The Kaplan-Meier Plotter online website analyzed the relationship between the expression of DHCR7 and SPTBN2 and the overall survival rate of BLCA patients.Furthermore,78 cases of BLCA admitted to our hospital from January 2018 to December 2019 were selected as the research subjects.The expression of DHCR7 and SPTBN2 in the tissues was detected using immunohistochemistry and the relationship with the clinical and pathological characteristics of BLCA was analyzed.A multivariate Logistic regression model was used to analyze the risk factors for poor prognosis in BLCA,and an early warning model was constructed and transformed into a risk scoring system.Evaluate the diagnostic efficacy and fitting degree of the model using the receiver operating characteristic (ROC) curve and Hosmer-Lemeshow (H-L) test.The 10-fold cross method verifies both the internal and external aspects of the model.Results:The GEPIA online website showed that the expression levels of DHCR7 and SPTBN2 proteins in BLCA tissues were higher than those in the normal control group (P＜0.05).The expression of DHCR7 and SPTBN2 in BLCA patients in stage IV was significantly increased compared to stage II (P=0.001 91,0.006 2,respectively).As the expression levels of DHCR7 and SPTBN2 increased,the survival rate of patients decreased (Logrank P is 0.003 1,0.001 5,respectively).The expression of DHCR7 and SPTBN2 was statistically significant in patients with different TNM stages,tumor differentiation,and lymph node metastasis (χ2=6.167,5.080,5.092;χ2=8.621,4.807,4.734,all P＜0.05).TNM stage III-IV,poor differentiation,lymph node metastasis,high expression of DHCR7 and high expression of SPTBN2 were risk factors for poor prognosis in BLCA (P＜0.05).The area under the ROC curve (AUC) of the model group was 0.889,and the H-L test fit was good (χ2=6.089 9,P=0.297 6).The AUC of the validation group was 0.883,and the H-L test fitted well (χ2=9.264 9,P=0.099 0).Conclusion:The BLCA adverse prognosis risk warning model constructed based on DHCR7 and SPTBN2 has good diagnostic efficacy and can provide important reference value for predicting the adverse prognosis of BLCA.

References:

［1］DANESHMAND S.Bladder cancer:advances and innovations［J］.Eur Urol Focus,2020,6(4):613-614.
［2］DOBRUCH J,OSZCZUDLOWSKI M.Bladder cancer:current challenges and future directions ［J］.Medicina (Kaunas),2021,57(8):749.
［3］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2021,71(3):209-249.
［4］SONG Q,ZHOU R,SHU F,et al.Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer ［J］.Front Immunol,2022,13:958368.
［5］COMPERAT E,AMIN MB,CATHOMAS R,et al.Current best practice for bladder cancer:a narrative review of diagnostics and treatments ［J］.Lancet,2022,400(10364):1712-1721.
［6］FLAIG TW,SPIESS PE,ABERN M,et al.NCCN guidelines insights:bladder cancer,version 2.2022 ［J］.J Natl Compr Canc Netw,2022,20(8):866-878.
［7］PATEL VG,OH WK,GALSKY MD.Treatment of muscle-invasive and advanced bladder cancer in 2020 ［J］.CA Cancer J Clin,2020,70(5):404-423.
［8］陈康,邢基,朱少明,等.膀胱癌中TFAP2C的表达及预后相关性分析［J］.现代肿瘤医学,2022,30(17):3172-3177. CHEN K,XING J,ZHU SM,et al.Correlation analysis of TFAP2C expression and prognosis in bladder cancer ［J］.Modern Oncology,2022,30(17):3172-3177.
［9］钟明达,江芬,宋磊,等.MiR-133b通过抑制SOX4调节膀胱癌细胞的增殖、克隆形成和侵袭能力［J］.中南大学学报（医学版）,2022,47(04):407-415. ZHONG MD,JIANG F,SONG L,et al.MiR-133b regulates the proliferation,cloning and invasion of bladder cancer cells by inhibiting SOX4 ［J］.Journal of Central South University (Medical Edition),2022,47 (04):407-415.
［10］刘牟林,丁大朋.AHSG与CEA联合检测对膀胱癌的诊断价值［J］.国际检验医学杂志,2022,43(01):27-31. LIU ML,DING DP.Diagnostic value of AHSG and CEA in bladder cancer ［J］.International Journal of Laboratory Medicine,2022,43(01):27-31.
［11］LI Y,ZHOU Y,HUANG M,et al.DHCR7 promotes tumorigenesis via activating PI3K/AKT/mTOR signalling pathway in bladder cancer ［J］.Cell Signal,2023,102:110553.
［12］WEN J,LI J,LIANG X,et al.Association of polymorphisms in vitamin D-metabolizing enzymes DHCR7 and CYP2R1 with cancer susceptibility:A systematic review and Meta-analysis ［J］.Dis Markers,2021,2021:6615001.
［13］ZOU J,LIU S,LONG J,et al.High DHCR7 expression predicts poor prognosis for cervical cancer ［J］.Comput Math Methods Med,2022,2022:8383885.
［14］ZHOU X,LIN L,QI Y,et al.SPTBN2 promotes the progression of thyroid cancer by accelerating G1/S transition and inhibiting apoptosis ［J］.Dis Markers,2022,2022:2562595.
［15］WANG P,LIU T,ZHAO Z,et al.SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis ［J］.Cell Death Discov,2021,7(1):382.
［16］WU C,DONG B,HUANG L,et al.SPTBN2,a new biomarker of lung adenocarcinoma ［J］.Front Oncol,2021,11:754290.

Memo

Memo:
-
Last Update: 1900-01-01